OBJECTIVES Rising costs in oncology care often impact patients and families directly, making communication about costs and financial impacts of treatment crucial. Cost expenditures could offer opportunities for estimation and prediction, affording personalized conversations about financial impact. We sought to explore providers', patients', and caregivers' preferences towards implementing communication about cost, including when, how, and by whom such information might be provided. METHODS We conducted semi-structured phone interviews with a diverse population including 12 oncology providers, 12 patients, and 8 patient caregivers (N = 32). The constant comparative method was used to identify mutually agreed upon themes. RESULTS Participant groups differed in their concerns surrounding cost communication, namely whether they want to receive this information and how such information might impact provider and patient treatment decisions. All participants agreed that oncology providers should not be leading cost conversations. Patients and caregivers identified social workers or financial advisors as most equipped to communicate about cost. Participants emphasized timely cost conversations, ideally around the time of diagnosis. Participants favored various metrics of financial impact beyond overall costs of care including disability, days lost from work, and out-of-pocket expenses. CONCLUSION Cost transparency should be incorporated into usual care; however, there are several challenges to making cost conversations a part of everyday practice. Patients and family members need resources related to cost to aid in decision-making and those delivering cost information should have competency in oncology, financial advisement, and patient-centered care.

中文翻译：

---

进行有关癌症治疗成本的常规沟通：提供者，患者和护理人员的观点。

目的肿瘤治疗费用的上涨经常直接影响患者和家属，因此就费用和财务影响进行沟通至关重要。成本支出可以提供估计和预测的机会，提供有关财务影响的个性化对话。我们试图探讨提供者，患者和看护者在实施有关费用沟通方面的偏好，包括何时，如何以及由谁提供此类信息。方法我们对包括12名肿瘤科医师，12名患者和8名患者护理人员（N = 32）的不同人群进行了半结构化电话采访。恒定比较法用于确定相互同意的主题。结果参加者小组对成本沟通的关注有所不同，即他们是否要接收此信息以及这些信息如何影响提供者和患者的治疗决策。所有参与者都同意，肿瘤学提供者不应成为成本对话的领导者。患者和护理人员认为社会工作者或财务顾问最有能力就成本进行沟通。与会人员强调及时进行成本对话，最好是在诊断期间。参与者更喜欢各种财务影响指标，而不仅仅是总体护理成本，包括残疾，工作日损失和自付费用。结论成本透明性应纳入常规护理中。但是，使成本对话成为日常活动的一部分存在一些挑战。